Formulation and In-Vitro Evaluation of Fexofenadine HCl Nano Lipid Based Formulation
Keywords:
Fexofenadine, nanostructured lipid carriers, encapsulation efficiency, in vitro releaseAbstract
Introduction: Nanostructured lipid carriers (NLC’s) are second-generation lipid nanoparticles that are used as alternative colloidal drug carriers. Fexofenadine HCl, is a long-acting antihistamine that is used to treat annual hay fever, angioedema and chronic autoimmune hives.
Methods: Fexofenadine NLC was prepared using the ultra-sonication method followed by hot homogenization. Total six formulations were developed. All the formulations were evaluated for particle size analysis, encapsulation efficiency and drug release studies. The physical stability was conducted on optimized formulation for 3 months.
Results: The particle size of all the formulations was found in the range of 124± 0.12 to 231.4± 0.12 nm. The PDI was ranged between 0.204 ±0.002 to 0.273± 0.001. The zeta potential values for all the NLC formulations were found to be within the range of -22.21± 2.23 to -28.17± 1.31. Based on the physicochemical properties, F6 formulation was selected as the optimized formulation.
Conclusion: Fexofenadine NLC was developed using ultrasonication method and hot homogenization. The optimized formulation (F6) showed highest encapsulation efficiency, drug release and was stable for 3 months.
Downloads
Metrics
References
Abdel hameed A.H., Abdelhafez W.A., Saleh K., Mohamed M.S. (2022) Formulation, optimization, and in vivo evaluation of nanostructured lipid carriers loaded with Fexofenadine HCL for oral delivery. J. Drug Deliv. Sci. Technol. 74, 103607.
Abdelhameed A.H., Abdelhafez W.A., Saleh, K.I., Hamad, A.A., Mohamed M.S. (2023) Formulation and optimization of oral fast dissolving films loaded with nanosuspension to enhance the oral bioavailability of Fexofenadine HCL. J. Drug Deliv. Sci. Technol. 85, 104578.
Avula, P. R., Chettupalli, A. K., Chauhan, V., & Jadi, R. K. (2023). Design, formulation, in-vitro and in-vivo pharmacokinetic evaluation of Nicardipine-nanostructured lipid carrier for transdermal drug delivery system. Materials today: Proceedings.
Beloqui A, Solinis MA, Gascon AR. (2013). Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 166:115–23.
Chakraborty S, Shukla D, Jain A. (2009). Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interface Sci 335:242–9.
Charman WN. (2000). Lipids, lipophilic drugs and oral drug delivery- some emerging concepts. J Pharm Sci 89:967–78
Chettupalli, A. K., Ajmera, S., Amarachinta, P. R., Manda, R. M., & Jadi, R. K. (2023). Quality by Design approach for preparation, characterization, and statistical optimization of naproxen sodium-loaded ethosomes via transdermal route. Current Bioactive Compounds, 19(10), 79-98.
Chettupalli, A. K., Kakkerla, A., Jadi, R. K., Uppu, P., Ghazwani, M., Hani, U., ... & Haque, M. A. (2025). Design, development, and preclinical evaluation of pirfenidone-loaded nanostructured lipid carriers for pulmonary delivery. Scientific Reports, 15(1), 11390.
Chettupalli, A. K., Unnisa, A., Peddapalli, H., Jadi, R. K., Anusha, K., & Amarachinta, P. R. (2025). Development and evaluation of empagliflozin-loaded solid lipid nanoparticles: Pharmacokinetics and pharmacodynamics for oral delivery. Intelligent Pharmacy.
Choudhury A, Laskar RE, Deka D, Sonowal K, Saha S, Dey BK. (2021) A review on nanoparticle: types, preparation and its characterization. Res J Pharm Technol. 14(3):1815-22.
D and Bielory L. (2008) Fexofenadine hydrochloride in the treatment of allergic disease: a review. Journal of Asthma and Allergy 1: 19-29.
Eedara B.B., Nyavanandi D., Narala, S., Veerareddy P.R., Bandari S. (2021) Improved Dissolution Rate and Intestinal Absorption of Fexofenadine Hydrochloride by the Preparation of Solid Dispersions: In vitro and in situ Evaluation. Pharmaceutics 13, 310.
Eslavath, R. N., Bakshi, V., & Jadi, R. K. (2019). Formulation Development and In Vitro Release Studies of Tenofovir-containing Microsponges. INNOSC Theranostics and pharmacological sciences, 2(2), 16-24.
Kaur IP, Bhandari R, Bhandari S, Kakkar V. (2008). Potential of solid lipid nanoparticles in brain targeting. J Control Release 127: 97–109.
Komati, S., Dasi, V., Jadi, R. K., & Padala, N. R. (2019). Formulation Development and Characterization of Atazanavir Sulphate Controlled Release Non-Effervescent Floating Matrix Tablets. Journal of Drug Delivery & Therapeutics, 9.
Korsmeyer RW, Gurny R, Doelker EM, (1983). Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 15: 25–35.
Kumar MNR. (2000). Nano and microparticles as controlled drug delivery devices. J Pharm Sci 3:234–58.
Liu D, Liu Z, Wang L, (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 85:262–9.
M.G. Shah, M. Tajmal, R. Karki. (2020) Formulation and evaluation of fexofenadine hydrochloride loaded chitosan nanoparticles. Int. J. Pharm. Sci. Res. 11(6): 2969-2975.
Muller RH, Maassen S, Weyhers H, Mehnert W. (1996). Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 4: 161–70.
Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 50:161–77.
Muller RH, Petersen RD, Hommoss A, Pardeike J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59:522–30.
Nasr A.M., Qushawy M.K., Elkhoudary M.M., Gawish, A.Y., Elhady, S.S., Swidan, S.A. (2020) Quality by Design for the Development and Analysis of Enhanced In-Situ Forming Vesicles for the Improvement of the Bioavailability of Fexofenadine HCl in vitro and in vivo. Pharmaceutics, 12, 409.
Nisharani S, Ranpise NS, Korabu SS, Ghodake VN. (2014). Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 116:81–7.
O’Driscoll CM, Griffin BT. (2008). Biopharmaceutical challenges associated with drugs with low aqueous solubility- the potential impact of lipid-based formulations. Adv Drug Deliv Rev 60: 617–24.
Pandala, S., Bakshi, V., & Jadi, R. K. (2019). Formulation Development and in vitro characterization of zolmitriptan controlled release drug delivery systems. INNOSC Theranostics Pharmacol. Sci, 2(1), 6-11.
Patel, S., Bhandari, R., & Kumar, P. (2019). Development and validation of a UV spectrophotometric method for the determination of Fexofenadine Hydrochloride in bulk and tablet formulations. Research Journal of Pharmacy and Technology, 12(2), 879-883.
Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110–11.
Priyanka K, Sathali AA. (2012). Preparation and evaluation of montelukast sodium loaded solid lipid nanoparticles. J Young Pharm 4:129–37.
Raj R, Mongia P, Ram A, Jain NK. (2015). Enhanced skin delivery of aceclofenac via hydrogel-based solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. DOI: 10.3109/ 21691401.2015.1036997.
Ramasamy T, Khandasami US, Ruttala H, Shanmugam S. (2012). Development of solid lipid nanoparticles enriched hydrogels for topical delivery of anti-fungal agent. Macromol Res 20:682–92.
Ranpise NS, Korabu SS, Ghodake VN. (2014). Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 116:81–7.
Sapavatu, S. N., & Jadi, R. K. (2019). Formulation development and characterization of gastroretentive drug delivery systems of loratadine. Int. J. Appl. Pharm, 11, 91-99.
Sapavatu, S. N., & Jadi, R. K. (2020). Development of floating drug delivery system for loratadine: in vitro and in vivo evaluation. International journal of pharmaceutical sciences and research, 11, 3021-2.
Sapavatu, S. N., Chinthala, R., & Jadi, R. K. (2020). An overview on pharmacokinetics of polymeric nanoparticles intended for oral delivery. Journal of Young Pharmacists, 12(3)
Sharaff, C. S., Renukuntla, P., Peddapalli, H., Kuchukuntla, M., Bakshi, V., & Jadi, R. K. (2024). Formulation, development, and characterization of loratadine emulgel. Journal of Applied Pharmaceutical Research, 12(2), 42-50.
Sultan A.A., El Nashar N.F., Ashmawy S.M., El Maghraby G.M. (2022) Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation. Int. J. Nanomed. 17, 3543–3560.
Togaru, V., Venisetty, R. K., Bakshi, V., & Jadi, R. K. (2017). Formulation Development and In Vitro Evaluation of Propranolol Hydrochloride Extended Release Matrix Tablets. Emergent Life Sciences Research, 3, 38-47.
Wen X, Tan F, Jing Z, Liu Z. (2004). Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin. J Pharm Biomed Anal 34:517–23.
Xie S, Zhu L, Dong Z, (2011). Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces 83:382–7.
Zhang L, Han L, Sun X, (2012). The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia 83: 678–89.
Zhuang CY, Li N, Wang M, (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179–85.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
